Cite
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
MLA
Xiaoyong Fu, et al. “Overcoming Endocrine Resistance Due to Reduced PTEN Levels in Estrogen Receptor-Positive Breast Cancer by Co-Targeting Mammalian Target of Rapamycin, Protein Kinase B, or Mitogen-Activated Protein Kinase Kinase.” Breast Cancer Research, vol. 16, no. 5, Oct. 2014, pp. 1–32. EBSCOhost, https://doi.org/10.1186/s13058-014-0430-x.
APA
Xiaoyong Fu, Creighton, C. J., Biswal, N. C., Kumar, V., Shea, M., Herrera, S., Contreras, A., Gutierrez, C., Tao Wang, Nanda, S., Giuliano, M., Morrison, G., Nardone, A., Karlin, K. L., Westbrook, T. F., Heiser, L. M., Anur, P., Spellman, P., Guichard, S. M., & Smith, P. D. (2014). Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Research, 16(5), 1–32. https://doi.org/10.1186/s13058-014-0430-x
Chicago
Xiaoyong Fu, Chad J. Creighton, Nrusingh C. Biswal, Vijetha Kumar, Martin Shea, Sabrina Herrera, Alejandro Contreras, et al. 2014. “Overcoming Endocrine Resistance Due to Reduced PTEN Levels in Estrogen Receptor-Positive Breast Cancer by Co-Targeting Mammalian Target of Rapamycin, Protein Kinase B, or Mitogen-Activated Protein Kinase Kinase.” Breast Cancer Research 16 (5): 1–32. doi:10.1186/s13058-014-0430-x.